Europe - PRIME Designation for BJT-778 in chronic HDV

he EMA has granted a PRIME Designation to BlueJay Therapeutics' BJT-778 for the treatment of Chronic Hepatitis Delta Virus (HDV) infection.

The application for PRIME designation was based on data from non-clinical studies, along with interim results from the company’s Phase 1/2 study that included subjects with chronic HDV.

As a reminder, BJT-778 is a IgG1 fully human monoclonal antibody which inhibit the expression of hepatitis B virus (HBV) surface antigen (HBsAg), for the potential treatment of chronic hepatitis B virus (CHB) and chronic hepatitis D virus (HDV) infection.